1 / 31

ANXIOLYTIC and SEDATIVE- HYPNOTIC DRUGS

ANXIOLYTIC and SEDATIVE- HYPNOTIC DRUGS Prof. Martínková 2006. Anxiolytic and sedative-hypnotic drugs. A sedative-hypnotic drug (terminology) Sedation can be defined as

caitir
Download Presentation

ANXIOLYTIC and SEDATIVE- HYPNOTIC DRUGS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ANXIOLYTIC and SEDATIVE- HYPNOTIC DRUGS Prof. Martínková 2006

  2. Anxiolytic and sedative-hypnotic drugs A sedative-hypnotic drug (terminology) Sedation can be definedas a supression of responsiveness to a constant level of stimulation, with decreased spontaneous activity and ideation.

  3. Anxiolytic and hypnotic drugs Ah y p n o t i c drug should produce drowsiness and encourage the onset and maintenance of a state of „sleep“ that as far as possible resembles the natural state of sleep. H y p n o t i ceffects involve more pronounced depression of the CNS than s e d a t i o n, and this can be achieved with most sedative drugs simply by increasing the dose.

  4. Anxiolytic and hypnotic drugs A n x i e t y In anxiety states the fear response to threatening stimuli occur in an anticipatory manner independently of external events. Among other the fear response includes defensive behaviours, autonomic reflexes, arousal and alertness, corticoid secretion and negative emotions. An effective anxiolytic agent should reduce anxiety and exert a calming effect - sedation - with little or no effect on motor and menthal function.

  5. Anxiolytic and hypnotic drugs (Fig 1) Graded dose-dependent depression of the CNS function is a characteristic of sedative-hypnotics. However, individual drugs differ in the relationship between the dose and the degree of CNS depression (see Fig 1). The linear slope for drug A is typical of many of the older sedative-hypnotics. With such drugs, an increarse in dose above that needed for hypnosis may lead to a state of general anesthesia. At still high doses, sedative-hypnotics may depress respiratory and vasomotor centres in the medulla, leading to coma and death.

  6. Anxiolytic and hypnotic drugs (Fig 1) Deviation from a linear dose-response relationship, as shown for drug B, will require proportionately greater dosage increments in order to achive CNS depression more profound than hypnosis. This appears to be the case for most drugs of the benzodiazepine class, and the greater margin of safety is an important reason for their clinical use to treat anxiety states and sleep disorders.

  7. Anxiolytic and hypnotic drugs Anxiety disorders include: - generalised anxiety disorder (an ongoing state of excessive anxiety lacking any clear reason ) - panic disorder (attacks of overwhelming fear occuring in association with somatic symptoms (sweating, tachycardia, chest pain) - phobias (strong fears of specific things or situation (snakes, flying) - postraumatic stress disorder (anxiety triggered by insistent recall of past stressful experiences

  8. Anxiolytic and hypnotic drugs • In most developed countries anxiolytic drugs are • among the most frequently prescribed drugs • Classes: • benzodiazepines • newer drugs: • 5 -HT1A -receptor agonists (buspiron) • zolpidem, zaleplon • miscellaneous other drugs • older sedative-hypnotics • barbiturates (obsolete)

  9. Anxiolytic and hypnotic drugs • benzodiazepines • Pharmacodynamics:(BZ) act selectively • on gamma-aminobutyric acid A (GABAA) receptors, • which mediate fast inhibitory synaptic transmission through the CNS. They bind specifically to a regulatory site of the receptor, distinct from the GABA binding site and act allosterically to increase the affinity of GABA for the receptors. • By facilitating the opening of GABA activated chloride-channels BZenhancethe response to GABA. • The antagonist – f l u m a z e n i l

  10. Anxiolytic and hypnotic drugs Fig 2: A model of the GABAA receptor-chloride ion channel macromolecular complex. The complex consists of five or more membrane-spanning subunits. GABA appears to interact with alpha or beta subunits triggering chloride channel opening with resultant membrane hyperpolarization. Binding of BZs to gamma subunits facilitates the process of channel opening.

  11. Anxiolytic and hypnotic drugs - benzodiazepines (BZ) • Pharmacokinetics: • absorption: well absorbed if given orally , Cmax reached in about 1 h • binding:strongly bound to plasma proteins • distribution: large Vd: accumulation in body fat (high • lipid solubility) • metabolism:(Fig 2): • hydroxylation • conjugation with glucuronic acid • short-, medium- and long-acting BZ • the role of N-desmethyldiazepam

  12. Anxiolytic and hypnotic drugs - benzodiazepines (BZ) Fig.3

  13. Anxiolytic and hypnotic drugs – benzodiazepines (BZ) • Fig.3 : demonstrates • the short-acting drugs are those that are metabolised directly by conjugation with glucuronide. • gradual bild-up and slow disappearance of nordazepam from the plasma gives long-acting drugs. • RememberAGE: advancing age affects the rate of oxidative reactions more than that of conjugation. • the effect of long-acting BZs tends to increase with age (drowsiness and confusion)

  14. Anxiolytic and hypnotic drugs – benzodiazepines (BZ) • Pharmacological effects and uses: • The main effects: • reduction of anxiety and agression • sedation and induction of sleep • reduction of muscle tone and coordination • anticonvulsant effects • anterograde amnesia

  15. Anxiolytic and hypnotic drugs – benzodiazepine (BZ) • reduction of anxiety and agression • Note: BZ may paradoxically produce an increase • in irritability and aggression in some individuals • (particularly if short- acting drugs are given (triazolam) • sedation and induction of sleep • BZs decreasethe timetaken to get to sleep • increase the total durationof sleep (only in subjects who normally sleep for less than about 6 hours each night)

  16. Anxiolytic and hypnotic drugs – benzodiazepines (BZ) REM sleep ( rapid eye movement) is less affected if compared with the same effect of other hypnotics. Is that important? Yes, artificial interruption of REM sleep causes irritability and anxiety even if the total amount of sleep is not reduced).

  17. Anxiolytic and hypnotic drugs – benzodiazepines (BZ) • reduction of muscle tone and coordination • may be clinically useful: increased muscle tone is a common feature of anxiety states and may contribute to pains (headache). Influence of manual skills (!) • anticonvulsant effects (GABAA receptors) • clonazepam to treat epilepsy • diazepam (i.v.) status epilepticusto control life-threatening seizures • anterograde amnesia • BZs obliterate memoryof events experienced while under their influence

  18. Anxiolytic and hypnotic drugs – benzodiazepines (BZ) • Unwanted effects • acute overdosage • effects occuring during normal therapeutic use • tolerance and dependence • acute overdosage (BZs are relatively safe in overdose) • BZs produce prolonged sleep, without serious depression of respiration or cardiovascular function • Severe even life-threatening respiratory depression may appear in BZ combination with other CNS depressants, particularly alcohol. • Acute overdosage can be counteracted withflumazenil

  19. Anxiolytic and hypnotic drugs – benzodiazepines (BZ) • unwanted effects occuring duringtherapeuticuse • ---Influence of manual skills (such as driving performance) due to drowsiness, confusion, amnesia and impaired coordination • --- enhance of depressant action of other drugs (in a more than additive way) • tolerance , dependence • Tolerance (gradual escalation of dose needed to produce the required effect) occurs with all BZs. T.appears to represent a change at the receptor level. • Dependence –In human subjects and patients, stopping BZ treatment after weeks and months causes an increase in symptoms of anxiety, together with tremor and dizziness.

  20. Anxiolytic and hypnotic drugs – benzodiazepines (BZ) The withdrawal syndrome: short acting BZs cause more abrupt withdrawal effects Addiction (-craving -severe psychological dependence) is not a major problem.

  21. Anxiolytic and hypnotic drugs - 5 -HT1A -receptor agonists • newer drugs • 5 -HT1A -receptor agonists • Buspiron-anxiolytic effects take days or weeks to develop.That is the most distinctive drug in terms of antianxiety actions, since these are achieved with minimal effects on psychomotor functions. • Unwanted effects • appear to be less troublesome: dizziness, nauzea, headache, • not sedation or loss of coordination

  22. Anxiolytic and hypnotic drugs –zoplidem, zaleplon • Zolpidempharmacodynamics • binds selectively to the BZ1 subtype of BZ receptors and • facilitates GABA-mediated neuronal inhibition • like the BZs, the actions of zolpidem are antagonised by • f l u m a z e n i l • minimal muscle relaxing and anticonvulsant effects • the risk of development of tolerance and dependence • with extended use is less than with the use of • hypnotic BZs • pharmacokinetics • rapidly metabolized to inactive metabolites by the liver, T1/2 1.5-3.5 h. Dosage reduction in hepatic dysfuction, elderly.

  23. Anxiolytic and hypnotic drugs –zoplidem, zaleplon Ind- short-term treatment of insomnia Zaleplon resembles zolpidem, t1/2 = 1h Rapid onset and short duration of action are favorable properties for those patients who have difficulty falling asleep.

  24. Anxiolytic and hypnoptic drugs – miscellaneous other drugs miscellaneous other drugs- older sedative-hypnotics: meprobamate, glutethimide rarely used

  25. Anxiolytic and hypnotic drugs – barbiturates (BA) • barbiturates (obsolete) • BA: the sleep-inducing properties were discovered early • in the 20th century . Until the 1960s, they formed the largest • group of hypnotics and sedatives in clinical use. • Pharmacodynamics: • BA share with BZs the ability to enhance the action of GABA, • but they bind to a different site of the GABAA-receptor/chloride • channel- their action is less specific.

  26. Anxiolytic and hypnotic drugs – barbiturates (BA) • Disadvantage of use: • if given in a large dose—death from respiratory and • cardiovascular depression (flumazenil not effective) • a high degree of tolerance: BA strongly induce the synthesis • and activity of hepatic CYP450 and conjugating enzymes • thus increasing the rate of metabolic degradation of many other drugs • --- drug-drug interactions • . dependence • BA are now little used • as anxiolytic and hypnotic drugs

  27. Anxiolytic and hypnotic drugs – barbiturates (BA) • BA in practical use • use as sedative and hypnotic agents is no longer • recommended • BAs are mainly used: • in anaesthesia - thiopental (i.v.) • treatment of epilepsy - phenobarbital

  28. Anxiolytic and hypnotic drugs - benzodiazepines (BZ) Fig.1.

More Related